Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada

@inproceedings{Chung2021EffectivenessOB,
  title={Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada},
  author={H. Chung and S. He and Saima Nasreen and Maria E. Sundaram and Sarah A. Buchan and S. E. Wilson and B. Chen and Andrew J. Calzavara and Deshayne B. Fell and Peter C. Austin and Kenneth J Wilson and Kevin L. Schwartz and Kevin Antoine Brown and J. B. Gubbay and Nicole E. Basta and Salaheddin M. Mahmud and Christiaan H. Righolt and Lawrence W. Svenson and Sarah E Macdonald and Naveed Zafar Janjua and Mina Tadrous and J. C. Kwong},
  booktitle={medRxiv},
  year={2021}
}
Objectives: To estimate the effectiveness of one and two doses of mRNA COVID-19 vaccines against symptomatic infection and severe outcomes. Design: Using a test-negative design study and linked laboratory, vaccination, and health administrative databases, we estimated adjusted vaccine effectiveness (aVE) against symptomatic infection and severe outcomes (hospitalization or death) using multivariable logistic regression. Setting: Ontario, Canada between 14 December 2020 and 19 April 2021… 
Effectiveness of COVID-19 vaccines against variants of concern, Canada
TLDR
The findings suggest that even a single dose of these 3 vaccine products provide good to excellent protection against symptomatic infection and severe outcomes caused by the 4 currently circulating variants of concern, and that 2 doses are likely to provide even higher protection.
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
TLDR
Two doses of mRNA-1273 were highly effective against all SARS-CoV-2 variants, especially against hospital admission with covid-19, however, vaccine effectiveness against infection with the delta variant moderately declined with increasing time since vaccination.
Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence.
TLDR
The Costa Rican vaccination programme that administered Pfizer and Oxford vaccines are highly effective to prevent COVID-19-related hospitalisations after the Delta variant had become dominant, justifying the continuation of the national policy of delaying the application for the second dose of the Pfizer vaccine to accelerate the vaccination and increase the number of people being vaccinated.
mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged >=16 Years in the United States, February to May 2021
TLDR
Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care and test-negative design, and VE of mRNA vaccines against CO VID-19 was 91% for full vaccination and 75% for partial vaccination.
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
TLDR
Covid-19 vaccines in the United States were highly effective against SARS-CoV-2 infection requiring hospitalization, ICU admission, or an emergency department or urgent care clinic visit.
Timing of Breakthrough Infection Risk After Vaccination Against SARS-CoV-2
TLDR
A case-cohort design provided an efficient means to identify strong protective effects associated with SARS-CoV-2 vaccination, particularly after the second dose of vaccine, but this effect appeared to wane once more than 6 months had elapsed since vaccination.
Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis
TLDR
The effectiveness of COVID-19 vaccines were noted to offer higher protection against the DV among populations who received two vaccine doses compared with the unvaccinated population, in order to have herd immunity to break the chain of transmission and gain greater overall population protection more rapidly.
Age-Specific Changes in Virulence Associated with SARS-CoV-2 Variants of Concern
TLDR
SARS-CoV-2 VOCs appear to be associated with increased relative virulence of infection in all age groups, though low absolute numbers of outcomes in younger individuals make estimates in these groups imprecise.
Age-Specific Changes in Virulence Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern
  • D. Fisman, A. Tuite
  • Medicine
    Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
  • 2022
TLDR
SARS-CoV-2 VOCs appear to be associated with increased relative virulence of infection in all age groups, though low absolute numbers of outcomes in younger individuals make estimates in these groups imprecise.
...
1
2
...

References

SHOWING 1-10 OF 23 REFERENCES
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
TLDR
This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
Effects of BNT162b2 mRNA vaccine on Covid-19 infection and hospitalisation among older people: matched case control study for England
TLDR
The nationwide vaccination of older adults in England with the BNT162b2 mRNA vaccine reduced the burden of Covid-19 and resulted in a reduction in hospitalisations and infections.
Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities
TLDR
Effectiveness was uniform for men and women yet declined mildly but significantly with age and for patients with specific chronic comorbidities, most notably type 2 diabetes.
The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence
TLDR
An effectiveness of 51% of BNT162b2 vaccine against SARS-CoV-2 infection 13-24 days after immunization with the first dose is demonstrated, and vaccination with the second dose should be continued to attain the anticipated protection.
Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People
TLDR
A single dose of the BNT162b2 mRNA and ChAdOx1 vaccines resulted in substantial reductions in the risk of COVID-19 related hospitalisation in Scotland.
Early evidence of COVID-19 vaccine effectiveness within the general population of California
TLDR
O Ongoing vaccination efforts are preventing SARS-CoV-2 infection in the general population in California, and vaccine hesitancy did not significantly differ by age, sex, household income, or race/ethnicity.
FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system
TLDR
Building upon the previous randomized trials of these vaccines, this study demonstrates their real-world effectiveness in reducing the rates of SARS-CoV-2 infection and COVID-19 severity among individuals at highest risk for infection.
Estimating real-world COVID-19 vaccine effectiveness in Israel
TLDR
Using counts of positive and hospitalized cases of vaccinated individuals, sensitive estimations of the vaccine effectiveness are provided by correcting to daily case incidence, finding high effectiveness of 66-85% in reducing SARS-CoV-2 positive cases and over 90%" in reducing severe hospitalizations.
Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study
TLDR
Where testing is limited, the results suggest that risk factors may be better estimated using population comparators rather than test-negative comparators, and there was less variability in testing by social determinants across analytic designs.
Postlicensure Evaluation of COVID-19 Vaccines.
TLDR
This work describesential methodologic challenges with using the commonly applied “test-negative” case-control design1 for evaluating COVID-19 vaccines and proposes potential solutions for consideration.
...
1
2
3
...